Ferring, a research-driven, specialty biopharmaceutical group, and The Blackstone Group agreed to invest $570m in FerGene, a new gene therapy company and Ferring subsidiary. "Bringing a novel gene therapy to the market requires dedicated focus and capabilities, and FerGene, a Ferring company, will have the resources and team needed to help us potentially bring nadofaragene firadenovec to patients. Through this new joint financing model between Ferring and Blackstone Life Sciences, we aim to ensure more people with high-grade, BGC unresponsive, non-muscle invasive bladder cancer may benefit from this novel gene therapy if approved,” Frederik Paulsen, Ferring Pharmaceuticals Chairman.